AU2020268684C1 - Variant domains for multimerizing proteins and separation thereof - Google Patents

Variant domains for multimerizing proteins and separation thereof

Info

Publication number
AU2020268684C1
AU2020268684C1 AU2020268684A AU2020268684A AU2020268684C1 AU 2020268684 C1 AU2020268684 C1 AU 2020268684C1 AU 2020268684 A AU2020268684 A AU 2020268684A AU 2020268684 A AU2020268684 A AU 2020268684A AU 2020268684 C1 AU2020268684 C1 AU 2020268684C1
Authority
AU
Australia
Prior art keywords
region
antibody
amino acid
heavy chain
variation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020268684A
Other languages
English (en)
Other versions
AU2020268684B2 (en
AU2020268684A1 (en
Inventor
Richard BONNEAU
Cornelis Adriaan De Kruif
Peter Brian SILVERMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus NV
Original Assignee
Merus NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus NV filed Critical Merus NV
Publication of AU2020268684A1 publication Critical patent/AU2020268684A1/en
Application granted granted Critical
Publication of AU2020268684B2 publication Critical patent/AU2020268684B2/en
Priority to AU2025208511A priority Critical patent/AU2025208511A1/en
Assigned to MERUS B.V. reassignment MERUS B.V. Request to Amend Deed and Register Assignors: MERUS N.V.
Publication of AU2020268684C1 publication Critical patent/AU2020268684C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2020268684A 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof Active AU2020268684C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025208511A AU2025208511A1 (en) 2019-05-09 2025-07-25 Variant domains for multimerizing proteins and separation thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09
EP19173633.9 2019-05-09
PCT/NL2020/050298 WO2020226502A2 (en) 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025208511A Division AU2025208511A1 (en) 2019-05-09 2025-07-25 Variant domains for multimerizing proteins and separation thereof

Publications (3)

Publication Number Publication Date
AU2020268684A1 AU2020268684A1 (en) 2021-12-09
AU2020268684B2 AU2020268684B2 (en) 2025-07-03
AU2020268684C1 true AU2020268684C1 (en) 2026-04-02

Family

ID=66476558

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020268684A Active AU2020268684C1 (en) 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof
AU2025208511A Pending AU2025208511A1 (en) 2019-05-09 2025-07-25 Variant domains for multimerizing proteins and separation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025208511A Pending AU2025208511A1 (en) 2019-05-09 2025-07-25 Variant domains for multimerizing proteins and separation thereof

Country Status (16)

Country Link
US (1) US20210054049A1 (cg-RX-API-DMAC7.html)
EP (1) EP3966238A2 (cg-RX-API-DMAC7.html)
JP (2) JP7760377B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017909A (cg-RX-API-DMAC7.html)
CN (2) CN114702587A (cg-RX-API-DMAC7.html)
AR (1) AR118898A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020268684C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022405A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139402A1 (cg-RX-API-DMAC7.html)
IL (1) IL287928A (cg-RX-API-DMAC7.html)
MA (1) MA55884A (cg-RX-API-DMAC7.html)
MX (1) MX2021013646A (cg-RX-API-DMAC7.html)
PH (1) PH12021552833A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112399PA (cg-RX-API-DMAC7.html)
TW (1) TW202108613A (cg-RX-API-DMAC7.html)
WO (1) WO2020226502A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094318A1 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
MX2023007028A (es) * 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
MX2023015461A (es) * 2021-06-17 2024-01-18 Fapon Biotech Inc Inmunoglobulina quimerica.
CN121824747A (zh) 2022-12-27 2026-04-10 美勒斯公司 产生双重特异性蛋白的方法
TW202544033A (zh) 2024-04-15 2025-11-16 荷蘭商美勒斯公司 Cd3結合結構域
TW202608928A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
TW202608927A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體-藥物偶聯物
WO2026013015A1 (en) 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040306A1 (en) * 1999-12-06 2001-06-07 Biosite Diagnostics, Inc. Human antibodies as detection reagents
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
EP2009101A1 (en) * 2006-03-31 2008-12-31 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2013055809A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
WO2013157954A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2017213267A1 (en) * 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins
US20180009908A1 (en) * 2015-01-22 2018-01-11 Eli Lilly And Company IgG Bispecific Antibodies and Processes for Preparation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP2014511836A (ja) * 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. ヘテロ二量体免疫グロブリン
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
BR112014010257A2 (pt) * 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2017218698A1 (en) * 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
TWI917306B (zh) 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
WO2001040306A1 (en) * 1999-12-06 2001-06-07 Biosite Diagnostics, Inc. Human antibodies as detection reagents
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP2009101A1 (en) * 2006-03-31 2008-12-31 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2013055809A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
WO2013157954A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US20180009908A1 (en) * 2015-01-22 2018-01-11 Eli Lilly And Company IgG Bispecific Antibodies and Processes for Preparation
WO2017213267A1 (en) * 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins

Also Published As

Publication number Publication date
WO2020226502A9 (en) 2022-03-03
AU2025208511A1 (en) 2025-08-14
JP2025120179A (ja) 2025-08-15
CN114702587A (zh) 2022-07-05
BR112021022405A2 (pt) 2022-04-19
SG11202112399PA (en) 2021-12-30
WO2020226502A2 (en) 2020-11-12
CN114430745A (zh) 2022-05-03
US20210054049A1 (en) 2021-02-25
NZ782091A (en) 2025-08-29
AU2020268684B2 (en) 2025-07-03
AU2020268684A1 (en) 2021-12-09
MA55884A (fr) 2022-03-16
KR20220017909A (ko) 2022-02-14
TW202108613A (zh) 2021-03-01
MX2021013646A (es) 2022-01-31
AR118898A1 (es) 2021-11-10
JP2022534674A (ja) 2022-08-03
JP7760377B2 (ja) 2025-10-27
CA3139402A1 (en) 2020-11-12
PH12021552833A1 (en) 2023-01-16
EP3966238A2 (en) 2022-03-16
IL287928A (en) 2022-01-01
WO2020226502A3 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
AU2021202578B2 (en) Compositions and methods related to engineered Fc constructs
JP6703560B2 (ja) 静電的ステアリング(electrostatic steering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
AU2020268684B2 (en) Variant domains for multimerizing proteins and separation thereof
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
KR20150035535A (ko) Ig-유사 분자의 제조방법 및 제조수단
JP2019089772A (ja) 改変抗体及びその作製方法
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK40105176A (en) Compositions and methods related to engineered fc constructs
HK1228927B (en) Compositions and methods related to engineered fc constructs
HK1228927A1 (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2025 AND 12 DEC 2025

HB Alteration of name in register

Owner name: MERUS B.V.

Free format text: FORMER NAME(S): MERUS N.V.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2025 AND 12 DEC 2025

FGA Letters patent sealed or granted (standard patent)